Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiac Event Risk Clear all
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
205
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Terminated No phase listed Observational

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Fullerton, California • Boca Raton, Florida • Homestead, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 24, 2026, 3:14 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT07448038
View directory record Official record
Conditions
Atherosclerosis
Interventions
Selnoflast, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Beverly Hills, California • Irvine, California • Santa Rosa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

NCT03395639
View directory record Official record
Conditions
Cardiac Disease
Interventions
Edoxaban, Standard of Care (SOC)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 24, 2026, 3:14 AM EDT
Terminated No phase listed Observational

Heart Failure and Risk of Re-Admissions Determined by Abnormal REVEAL Parameters

NCT01357408
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 24, 2026, 3:14 AM EDT
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 24, 2026, 3:14 AM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population

NCT00431405
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease, Coronary Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2007 · Synced Sep 24, 2026, 3:14 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

NCT03315143
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
119
States / cities
Birmingham, Alabama • Sheffield, Alabama • Mesa, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational

Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy

NCT00753233
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 21 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 24, 2026, 3:14 AM EDT
Suspended Phase 3 Interventional

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

NCT00353067
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
veliflapon (DG-031)
Drug
Lead sponsor
deCODE genetics
Industry
Eligibility
35 Years and older
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Sep 24, 2026, 3:14 AM EDT
Withdrawn No phase listed Observational

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

NCT01809730
View directory record Official record
Conditions
Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 24, 2026, 3:14 AM EDT
Recruiting Phase 3 Interventional

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Interventions
Lepodisiran, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
La Jolla, California • Northridge, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975
View directory record Official record
Conditions
Stroke, Myocardial Infarctions
Interventions
Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Clinical and Personal Information Shape Physicians' Risk Judgments

NCT07162376
View directory record Official record
Conditions
Major Adverse Cardiac Event (MACE)
Interventions
Personal Information Disclosure
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

NCT01327846
View directory record Official record
Conditions
Atherosclerosis
Interventions
Canakinumab, Placebo, Standard of care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
315
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 24, 2026, 3:14 AM EDT
Not listed No phase listed Observational

Heart Failure Event Advance Detection Trial

NCT04223271
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Decompensated Heart Failure
Interventions
Indicor
Diagnostic Test
Lead sponsor
Vixiar Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 24, 2026, 3:14 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
242
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational

Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

NCT01262222
View directory record Official record
Conditions
High Risk for Postoperative Cardiovascular Events
Interventions
endothelial function testing
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Color Priming and Patient Decision-Making in the Emergency Department: Priming "Threat" in Patients With Low-Risk Chest Pain

NCT04749147
View directory record Official record
Conditions
Chest Pain, Cardiac Event
Interventions
Black and White Printed Survey, Red Printed Survey
Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Effects of 9-18 Weeks of Intensive Cardiac Rehabilitation After a Major Cardiovascular Event in Patients With CVD

NCT05708313
View directory record Official record
Conditions
Cardiovascular Diseases, Lifestyle Risk Reduction
Interventions
lifestyle modification
Behavioral
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
65 Years to 85 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational

Genetic Risk Assessment of Defibrillator Events

NCT02045043
View directory record Official record
Conditions
Sudden Cardiac Death, Arrhythmias, Congestive Heart Failure, Cardiomyopathy
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
1,807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Results available

DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

NCT02666742
View directory record Official record
Conditions
Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
Interventions
DOAC, Aspirin
Drug
Lead sponsor
Kansas City Heart Rhythm Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 24, 2026, 3:14 AM EDT
Not listed No phase listed Observational

PREdicting Atrial Fibrillation or Flutter

NCT01851902
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Not listed
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational

Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant

NCT04118530
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, Atrial Fibrillation, Atrial Flutter
Interventions
HSCT Patients
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 24, 2026, 3:14 AM EDT